Literature DB >> 21692515

Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis.

X Christopher Yu1, Koman Joe, Yu Zhang, Andrea Adriano, Yaning Wang, Helene Gazzano-Santoro, Rodney G Keck, Galahad Deperalta, Victor Ling.   

Abstract

We report an efficient, high fidelity trypsin digestion method for peptide map analysis. This method minimizes artifacts caused by the sample preparation process, and we show its utility for the accurate determination of succinimide formation in a degraded monoclonal antibody product. A basic charge variant was detected by imaged capillary isoelectric focusing and was shown with reduced antigen binding and biological activity. Samples were reduced under denaturing conditions at pH 5.0, and digestion of the reduced protein with porcine trypsin was performed at pH 7.0 for 1 h. Following reversed phase high-performance liquid chromatography and online mass spectrometric analysis, succinimide formation was identified at Asp30 in the light chain. This result contrasts with the observation of only iso-Asp and Asp residues under conventional sample preparation conditions, which are therefore concluded to be artificially generated. The Asp30 residue is seen in the cocrystal structure model to participate in favorable charge interaction with an antigen molecule. Formation of succinimide and the resulting loss of negative charge are therefore hypothesized to be the degradation mechanism. After treatment of the degraded antibody sample to mildly alkaline pH conditions, we observed only Asp residue as the succinimide hydrolysis product and concurrent recovery of biological activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692515     DOI: 10.1021/ac200750u

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  20 in total

1.  Understanding the pathway and kinetics of aspartic acid isomerization in peptide mapping methods for monoclonal antibodies.

Authors:  June Kuang; Yuanqi Tao; Yuanli Song; Letha Chemmalil; Nesredin Mussa; Julia Ding; Zheng Jian Li
Journal:  Anal Bioanal Chem       Date:  2021-02-05       Impact factor: 4.142

2.  In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.

Authors:  Vikas K Sharma; Thomas W Patapoff; Bruce Kabakoff; Satyan Pai; Eric Hilario; Boyan Zhang; Charlene Li; Oleg Borisov; Robert F Kelley; Ilya Chorny; Joe Z Zhou; Ken A Dill; Trevor E Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 3.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

4.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

5.  Mass spectrometric distinction of in-source and in-solution pyroglutamate and succinimide in proteins: a case study on rhG-CSF.

Authors:  Mukesh Kumar; Amarnath Chatterjee; Anand P Khedkar; Mutyalasetty Kusumanchi; Laxmi Adhikary
Journal:  J Am Soc Mass Spectrom       Date:  2013-01-03       Impact factor: 3.109

6.  Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.

Authors:  David Ouellette; Chris Chumsae; Anca Clabbers; Czeslaw Radziejewski; Ivan Correia
Journal:  MAbs       Date:  2013-04-22       Impact factor: 5.857

7.  Mass Spectrometry Based Mechanistic Insights into Formation of Tris Conjugates: Implications on Protein Biopharmaceutics.

Authors:  Pradeep G Kabadi; Praveen Kallamvalliillam Sankaran; Dinesh V Palanivelu; Laxmi Adhikary; Anand Khedkar; Amarnath Chatterjee
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-03       Impact factor: 3.109

Review 8.  Forced degradation of recombinant monoclonal antibodies: A practical guide.

Authors:  Christine Nowak; Jason K Cheung; Shara M Dellatore; Amit Katiyar; Ram Bhat; Joanne Sun; Gomathinayagam Ponniah; Alyssa Neill; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2017-08-30       Impact factor: 5.857

Review 9.  In vitro and in vivo modifications of recombinant and human IgG antibodies.

Authors:  Hongcheng Liu; Gomathinayagam Ponniah; Hui-Min Zhang; Christine Nowak; Alyssa Neill; Nidia Gonzalez-Lopez; Rekha Patel; Guilong Cheng; Adriana Z Kita; Bruce Andrien
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

10.  Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies.

Authors:  Sheng Yin; Cinthia V Pastuskovas; Leslie A Khawli; John T Stults
Journal:  Pharm Res       Date:  2012-09-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.